Acute Hepatitis B

  • Aliye Bastug
  • Hurrem Bodur


Hepatitis B virus (HBV) is a hepatotropic virus that causes systemic infection, predominantly affecting the liver. The viral life cycle of HBV is known well enough that it is possible to control the viral replication with the specific antivirals. However, there is no cure yet for HBV infections. It is a major health problem since more than 2 billion people have been infected with HBV, globally. The spectrum of illness varies from acute hepatitis to chronic hepatitis which may lead to cirrhosis and/or hepatocellular carcinoma. The clinical phases of acute hepatitis B infections range from asymptomatic hepatitis to icteric and fulminant hepatitis. Acute viral hepatitis is usually self-limiting, especially in older than 5-year-old children, and the supportive treatment is enough in most of them. The prevention of infection is possible with the knowledge of transmission routes and administration of effective vaccination programs.


Acute hepatitis B Epidemiology Management Prevention 


  1. 1.
    Thio CL, Hawkins C. Hepatitis B virus and hepatitis delta virus chapter 148. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia, PA, Elsevier/Saunders; 2015. p. 1815–39.Google Scholar
  2. 2.
    Flaum A, Malmros H, Persson E. Eine nosocomiale icterus epidemic. Acta Med Scand Suppl. 1926;16:544.Google Scholar
  3. 3.
    Blumberg B, Alter H, Visnich S. A “new” antigen in leukemia sera. JAMA. 1965;191:541–6.CrossRefGoogle Scholar
  4. 4.
    Dane DS, Cameron C, Briggs M. Virus-like particles in serum of patients with Australia antigen associated hepatitis. Lancet. 1970;2:695–8.CrossRefGoogle Scholar
  5. 5.
    Galibert F, Mandart E, Fitoussi F, et al. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature. 1979;281:646–50.CrossRefGoogle Scholar
  6. 6.
    Sninsky JJ, Siddiqui A, Robinson WS, et al. Cloning and endo-nuclease mapping of the hepatitis B viral genome. Nature. 1979;279:346–8.CrossRefGoogle Scholar
  7. 7.
    Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64(1 Suppl):S4–S16. Scholar
  8. 8.
    Dienstang JL. In: Kasper DL, Harrison TR, editors. Acute viral hepatitis. Chapter 304 in Harrison’s principles of internal medicine. 18th ed. New York, McGraw-Hill: Medical Pub. Division; 2005.Google Scholar
  9. 9.
    Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol. 1988;69:2575–83.CrossRefGoogle Scholar
  10. 10.
    Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Belshaw R, Allain JP, et al. Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology. 2013;57:908–16.CrossRefGoogle Scholar
  11. 11.
    Abdou Chekaraou M, Brichler S, Mansour W, Le Gal F, Garba A, Deny P, et al. A novel hepatitis B virus (HBV) subgenotype D (D8) strain, resulting from recombination between genotypes D and E, is circulating in Niger along with HBV/E strains. J Gen Virol. 2010;91:1609–20.CrossRefGoogle Scholar
  12. 12.
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alpha-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–95.CrossRefGoogle Scholar
  13. 13.
    Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:1134–43.CrossRefGoogle Scholar
  14. 14.
    Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther. 2011;16:1169–86. Scholar
  15. 15.
    Sozzi V, Walsh R, Littlejohn M, Colledge D, Jackson K, Warner N, Yuen L, Locarnini SA, Revill PA. In vitro studies show that sequence variability contributes to marked variation in hepatitis B virus replication, protein expression, and function observed across genotypes. J Virol. 2016;90(22):10054–64.CrossRefGoogle Scholar
  16. 16.
    Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1–20. Google Scholar
  17. 17.
    World Health Organization (WHO). Guidelines on Hepatitis B and C testing. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.Google Scholar
  18. 18.
    World Health Organization (WHO). Global hepatitis report, April 2017. -hepatitis-report2017/en/.
  19. 19.
    The Centers for Disease Control and Prevention (CDC). Infectious diseases related to travel: Hepatitis B. Accessed 11 Nov 2017.
  20. 20.
    Schweitzer A, Horn J, Mikolajczyk R, Krause G, Ott J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. 2015;Vol 386.
  21. 21.
    The Centers for Disease Control and Prevention (CDC). National notifiable diseases surveillance system- United States, 2015. Atlanta, GA: US Department of Health and Human Services; 2015. Accessed 8 Nov 2017.
  22. 22.
    European Centre for Disease Prevention and Control. Annual epidemiological report 2016—Hepatitis B. [Internet]. Stockholm: ECDC; 2016. Accessed 7 Nov 2017.
  23. 23.
    Shiffman ML. Management of acute hepatitis B. Clin Liver Dis. 2010;14:75–91.CrossRefGoogle Scholar
  24. 24.
    Centers for Disease Control and Prevention. Hepatitis B information for health professionals: Hepatitis B FAQs for health professionals. 2016. Accessed 8 Nov 2017.
  25. 25.
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.CrossRefGoogle Scholar
  26. 26.
    Treichel U, Meyer zum Bu¨schenfelde KH, Stockert RJ, et al. The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J Gen Virol. 1994;75:3021–9.CrossRefGoogle Scholar
  27. 27.
    Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284:825–9.CrossRefGoogle Scholar
  28. 28.
    Ferrari C, Bertoletti A, Penna A, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest. 1991;88:214–22.CrossRefGoogle Scholar
  29. 29.
    Barker LF, Murray R. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. Am J Med Sci. 1972;263(1):27–33.CrossRefGoogle Scholar
  30. 30.
    Tillmann HL, Patel K. Therapy of acute and fulminant hepatitis B. Intervirology. 2014;57:181–8.CrossRefGoogle Scholar
  31. 31.
    McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599–603.CrossRefGoogle Scholar
  32. 32.
    Hoofnagle JH, DiBisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis. 1991;11:73–83.CrossRefGoogle Scholar
  33. 33.
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.CrossRefGoogle Scholar
  34. 34.
    Heathcote J, Elewaut A, Fedail S, Gangl A, Hamid S, Shah M. et al. Management of acute viral hepatitis. World Gastroenterology Organisation Practice Guidelines; 2003.Google Scholar
  35. 35.
    Jamma S, Hussain G, Lau DT. Current concepts of HBV/HCV coinfection: coexistence, but not necessarily in harmony. Curr Hepat Rep. 2010;9:260–9.CrossRefGoogle Scholar
  36. 36.
    Liaw YF, Lin SM, Sheen IS, et al. Acute hepatitis C virus super-infection followed by spontaneous HBeAg seroconversion and HBsAg elimination. Infection. 1991;19:250–1.CrossRefGoogle Scholar
  37. 37.
    Sagnelli E, Coppola N, Pisaturo M, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009;49:1090–7.CrossRefGoogle Scholar
  38. 38.
    Shukla NB, Poles MA. Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus. Clin Liver Dis. 2004;8:445–60.CrossRefGoogle Scholar
  39. 39.
    Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29:1306–10.CrossRefGoogle Scholar
  40. 40.
    Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921–1926.CrossRefGoogle Scholar
  41. 41.
    Clifford GM, Rickenbach M, Polesel J, Swiss HIV Cohort, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008;22:2135–41.CrossRefGoogle Scholar
  42. 42.
    Wai CT, Fontana RJ, Polson J, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat. 2005;12:192–8.CrossRefGoogle Scholar
  43. 43.
    Lee WM. Etiologies of acute liver failure. Semin Liver Dis. 2008;28:142–50.CrossRefGoogle Scholar
  44. 44.
    Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet. 2010;376:190–201.CrossRefGoogle Scholar
  45. 45.
    Michitaka K, Horiike N, Chen Y, Duong TN, Konishi I, Mashiba T, Tokumoto Y, Hiasa Y, Tanaka Y, Mizokami M, Onji M. Gianotti- Crosti syndrome caused by acute hepatitis B virus genotype D infection. Intern Med. 2004;43:696–9.CrossRefGoogle Scholar
  46. 46.
    Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, Cohen P, French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005;84:313–22.CrossRefGoogle Scholar
  47. 47.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRefGoogle Scholar
  48. 48.
    Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection—EASL special conference. J Hepatol. 2015;63:1238–53.CrossRefGoogle Scholar
  49. 49.
    World Health Organization (WHO). Immunization, vaccines and biologicals: Hepatitis B. (2013). Accessed 13 Nov 2017.
  50. 50.
    Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1–33.Google Scholar
  51. 51.
    Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135:796–800.CrossRefGoogle Scholar
  52. 52.
    Su TH, Chen PJ. Emerging hepatitis B virus infection in vaccinated populations: a rising concern? Emerg Microbes Infect. 2012;1(9):e27.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Goilav C, Piot P. Vaccination against hepatitis B in homosexual men. A review. Am J Med. 1989;87:21S–5S.CrossRefGoogle Scholar
  54. 54.
    Saari TN. Immunization of preterm and low birth weight infants. Pediatrics. 2003;112:193–8.CrossRefGoogle Scholar
  55. 55.
    Chen DS. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol. 2009;50:805–16.CrossRefGoogle Scholar
  56. 56.
    Use of Hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2011;60(50):1709–11.Google Scholar
  57. 57.
    Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. JAMA. 1985;253:1740–5.CrossRefGoogle Scholar
  58. 58.
    Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA. 1987;257:2612–6.CrossRefGoogle Scholar
  59. 59.
    The Centers for Disease Control and Prevention (CDC). Guidance for evaluating health-care personnel for Hepatitis B Virus protection and for administering postexposure management. MMWR. 2013;62(10):1–19.Google Scholar
  60. 60.
    Chun HM, Fieberg AM, Hullsiek KH, Infectious Disease Clinical Research Program HIV Working Group, et al. Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis. 2010;50:426–36.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Aliye Bastug
    • 1
  • Hurrem Bodur
    • 1
  1. 1.Department of Infectious Diseases and Clinical MicrobiologySaglik Bilimleri University Ankara Numune Education and Research HospitalAnkaraTurkey

Personalised recommendations